Somewhat Positive Media Coverage Somewhat Unlikely to Impact NuVasive (NUVA) Stock Price
Headlines about NuVasive (NASDAQ:NUVA) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. NuVasive earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news stories about the medical device company an impact score of 47.0101356475651 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern’s scoring:
- Spinal Trauma Devices Market to Reach a Valuation of US$4.7 Bn by 2023 (digitaljournal.com)
- Siemens Healthineers Partners With NuVasive (ryortho.com)
- What You Must Know About NuVasive Inc’s (NASDAQ:NUVA) 5.4% ROE (finance.yahoo.com)
- Global Orthopedic Products Market 2018 Analysis – NuVasive Inc., Medtronic PLC, Zimmer-Biomet Holdings (dailyl.com)
- NuVasive (NUVA) and AIT Therapeutics (AITB) Head to Head Analysis (americanbankingnews.com)
NuVasive stock opened at $69.38 on Friday. The company has a market capitalization of $3.58 billion, a PE ratio of 36.32, a PEG ratio of 1.91 and a beta of 0.69. NuVasive has a 1 year low of $44.62 and a 1 year high of $71.15.
NUVA has been the subject of a number of research reports. TheStreet raised shares of NuVasive from a “c+” rating to a “b-” rating in a report on Thursday, August 2nd. BidaskClub raised NuVasive from a “hold” rating to a “buy” rating in a research note on Friday, August 3rd. Zacks Investment Research downgraded NuVasive from a “hold” rating to a “sell” rating in a research note on Tuesday, July 3rd. Needham & Company LLC lowered their price objective on NuVasive from $69.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, August 1st. Finally, Cantor Fitzgerald started coverage on NuVasive in a research note on Thursday, May 31st. They issued a “neutral” rating and a $54.00 price objective for the company. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $64.06.
NuVasive Company Profile
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Recommended Story: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.